Catabasis Pharmaceuticals (ATXS) Upgraded by Zacks Investment Research to Buy

Catabasis Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Catabasis Pharmaceuticals Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Catabasis Pharmaceuticals traded down -$0.19 on Wednesday, reaching $7.53. 31366 shares of the stock traded hands, compared to its average volume of 88126. Shares of Catabasis Pharmaceuticals were trading at $7.53 on Wednesday. The firm’s 50 day moving average is $8.75 and its 200 day moving average is $13.21.Catabasis Pharmaceuticals has a 12 month low of $7.40 and a 12 month high of $47.82. While on yearly highs and lows, Catabasis Pharmaceuticals’s today has traded high as $7.77 and has touched $7.40 on the downward trend. See More Analyst Rating at: RATING

Catabasis Pharmaceuticals Earnings and What to expect: 

Catabasis Pharmaceuticals last announced its earnings results on August 8th, 2021. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by $0.06. Catabasis Pharmaceuticals has generated ($12.18) earnings per share over the last year (($56.99) diluted earnings per share). Earnings for Catabasis Pharmaceuticals are expected to decrease in the coming year, from $6.74 to ($3.04) per share. Catabasis Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Catabasis Pharmaceuticals are expected to decrease in the coming year, from $6.74 to ($3.04) per share. The P/E ratio of Catabasis Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Catabasis Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Catabasis Pharmaceuticals has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Catabasis Pharmaceuticals (ATXS) Moving Average Technical Analysis

5 day Moving Average is $7.48 And 5 day price change is -$0.21 (-2.71%)  with average volume for 5 day average is 56,360. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $8.72 and 20 day price change is -$1.79 (-19.21%) and average 20 day moving volume is 78,575. 50 day moving average is $8.75  and 50 day price change is -$1.53 ( -16.89%)  and with average volume for 50 days is : 207,988. 200 day moving average is $13.21  and 200 day price change is -$5.25 (-41.08%)  and with average volume for 200 days is : 435,466.

Other owners latest trading in Catabasis Pharmaceuticals :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 115,069 which equates to market value of $0.24M and appx 0.00% owners of Catabasis Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 125,946 which equates to market value of $0.27M and appx 0.00% owners of Catabasis Pharmaceuticals
  • On 8/18/2021 shares held by Ikarian Capital LLC were 532,298 which equates to market value of $1.12M and appx 0.10% owners of Catabasis Pharmaceuticals
  • In total Institutional ownership equates to for Catabasis Pharmaceuticals

See More Analyst Rating at: RATING